- Acquired by RxE2, Jan 2021
- Raised funding round, Apr 2020
About
Habitu is developing an interactive communication platform to help inform, engage, track, and personalize the patient experience while driving interventions based on behavior predictions in decentralized environments such as home hospitalization and clinical trials. Habitu's platform is designed to provide a seamless, continuous flow of information between the patient, supporting care circle (e.g. family), and medical or clinical teams, both on-site and off, along with self-treatment recommendations. The platform manages the patient's commitment to treatment, predicts treatment dropout, provides alerts and actionable insights to the medical or clinical staff, and recommends a mix of automated and human interventions.
Funding history · 1 round · — total
Q&A
- What is Habitu's primary business?
- Habitu develops an interactive communication platform aimed at informing, engaging, tracking, and personalizing the patient experience in decentralized environments like home hospitalization and clinical trials.
- When was Habitu acquired and by whom?
- Habitu was acquired by RxE2 in January 2021.
- Where is Habitu's headquarters located?
- Habitu's headquarters is located in Herzliya, Center District, Israel.
- When was Habitu founded?
- Habitu was founded in November 2018.
- Which sector does Habitu primarily operate in?
- Habitu's primary sector is Health Tech & Life Sciences.
- What technologies does Habitu utilize in its platform?
- Habitu's platform incorporates Platforms & Interfaces, Mobile technology, and Artificial Intelligence.
- Who are the target customers for Habitu's platform?
- Habitu targets customers in Healthcare & Life Sciences, specifically Life Sciences, Pharmaceuticals, Healthcare, Patients, and Providers.
Team · 2
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/18543012 |
Identifiers & details
| Former names | Fore Trial |
|---|---|
| Founded | 2018-11 |
| Status reason | Acquired (Inactive) by RxE2 on Jan 2021 - closed due to acquisition |
Acquisitions & public offerings
Acquired by RxE2 2021-01